Allergan and Valeant: Who’ll See the Bigger Benefit from Irritable Bowels?

Allergan (AGN) and Valeant Pharmaceuticals (VRX) both had treatments for IBS-D–analysts clearly don’t want to cheapen their work by writing irritable bowel syndrome with diarrhea–approved by the FDA. Barclays’ Douglas Tsao invited two gastroenterologists to discuss Valeant’s Xifaxan and Allergan’s Viberz: European Pressphoto Agency Xifaxan and Viberzi are important to Valeant Pharmaceuticals and Allergan respectively, albeit for [...]